InvestWiser

Infant Bacterial Therapeutics AB (publ)

IBT-BNasdaq StockholmHealthcareMarket value 924 m SEK
71.00SEK +1.7%
last day · Price as of 19 November 2026

The answer first

Does Infant Bacterial Therapeutics beat the market?

Yes, Infant Bacterial Therapeutics has beaten the market over the last year.

Infant Bacterial Therapeutics+52.4%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 22% of Nordic stocks

    • Quality16
    • Value1
    • Trend93

    No. 123 of 195 in healthcare

Max for seven days

Follow Infant Bacterial Therapeutics with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Infant Bacterial Therapeutics

From today, at a price of 71.00 SEK. Write why you follow Infant Bacterial Therapeutics, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Infant Bacterial Therapeutics

Your first answer is free, no account needed.

Do you own Infant Bacterial Therapeutics, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Infant Bacterial Therapeutics and a few more. Free, no card.

Past year against the exchange and Super Stock
Infant Bacterial Therapeutics+52.4%Stockholm (OMXSGI)+17.6%Super Stock+46.4%
18 November 202519 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Infant Bacterial Therapeutics has risen 52.4% over the past year, including dividends.
  • Overall, Infant Bacterial Therapeutics ranks better than 22% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 74.6%. The price is 73.3% below its peak now.

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

22

Quality, value and trend together. Better than 22% of Nordic stocks.

No. 123 of 195 in healthcare

Quality16
The company · Fundamentals: the accounts

Low Weaker accounts than most: low profitability, high debt or uneven results.

No. 174 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.00
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−281.6%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value1
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 189 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity28.7
  • P/SPrice divided by sales–
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend93
The share price · Technical: the price trend

High Tailwind in the share price: it has risen more than most over the last year.

No. 21 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months+6.0%
  • 6 months+34.5%
  • 9 months+26.8%
  • 12 months+52.4%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−12.1%
3 years, per year
−8.2%
5 years, per year
−0.9%
10 years, per year
+5.0%
Largest fall, 3 years
−74.6%
From a peak to the bottom
From the peak now
−73.3%
How far the price is from the peak
Volatility, 1 year
58.0%
How much the price swings over a year
Beta, 1 year
0.46
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Infant Bacterial Therapeutics

5 funds we follow own Infant Bacterial Therapeutics. The share is how much of the fund the stock makes up.

  • Sweden5

From the funds' latest known holdings.

About Infant Bacterial Therapeutics

Infant Bacterial Therapeutics AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 6 employees.

Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which has completed Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants.

See the full analysis of Infant Bacterial Therapeutics.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market